Buphenyl® (sodium phenylbutyrate) Tablets
Buphenyl® (sodium phenylbutyrate) Powder
Buphenyl® (sodium phenylbutyrate) Tablets for oral administration and Buphenyl® (sodium phenylbutyrate) Powder for oral, nasogastric, or gastrostomy tube administration contain sodium phenylbutyrate. Sodium phenylbutyrate is an off-white crystalline substance which is soluble in water and has a strong salty taste. Sodium phenylbutyrate also is freely soluble in methanol and practically insoluble in acetone and diethyl ether.
BUPHENYL is indicated as adjunctive therapy in the chronic management of patients with urea cycle disorders involving deficiencies of carbamylphosphate synthetase (CPS), ornithine transcarbamylase (OTC), or argininosuccinic acid synthetase (AS). It is indicated in all patients with neonatal-onset deficiency (complete enzymatic deficiency, presenting within the first 28 days of life). It is also indicated in patients with late-onset disease (partial enzymatic deficiency, presenting after the first month of life) who have a history of hyperammonemic encephalopathy. It is important that the diagnosis be made early and treatment initiated immediately to improve survival. Any episode of acute hyperammonemia should be treated as a life-threatening emergency.
BUPHENYL must be combined with dietary protein restriction and, in some cases, essential amino acid supplementation. (See Nutritional Supplementation subsection of the DOSAGE AND ADMINISTRATION section.)
Previously, neonatal-onset disease was almost universally fatal within the first year of life, even when treated with peritoneal dialysis and essential amino acids or their nitrogen-free analogs. However, with hemodialysis, use of alternative waste nitrogen excretion pathways (sodium phenylbutyrate, sodium benzoate, and sodium phenylacetate), dietary protein restriction, and, in some cases, essential amino acid supplementation, the survival rate in newborns diagnosed after birth but within the first month of life is almost 80%. Most deaths have occurred during an episode of acute hyperammonemic encephalopathy. Patients with neonatal-onset disease have a high incidence of mental retardation. Those who had IQ tests administered had an incidence of mental retardation as follows: ornithine transcarbamylase deficiency, 100% (14/14 patients tested); argininosuccinic acid synthetase deficiency, 88% (15/17 patients tested); and carbamylphosphate synthetase deficiency, 57% (4/7 patients tested). Retardation was severe in the majority of the retarded patients.
In patients diagnosed during gestation and treated prior to any episode of hyperammonemic encephalopathy, survival is 100%, but even in these patients, most subsequently demonstrate cognitive impairment or other neurologic deficits.
In late-onset deficiency patients, including females heterozygous for ornithine transcarbamylase deficiency, who recover from hyperammonemic encephalopathy and are then treated chronically with sodium phenylbutyrate and dietary protein restriction, the survival rate is 98%. The two deaths in this group of patients occurred during episodes of hyperammonemic encephalopathy. However, compliance with the therapeutic regimen has not been adequately documented to allow evaluation of the potential for BUPHENYL and dietary protein restriction to prevent mental deterioration and recurrence of hyperammonemic encephalopathy if carefully adhered to. The majority of these patients tested (30/46 or 65%) have IQ's in the average to low average/borderline mentally retarded range. Reversal of pre-existing neurologic impairment is not likely to occur with treatment and neurologic deterioration may continue in some patients.
Even on therapy, acute hyperammonemic encephalopathy recurred in the majority of patients for whom the drug is indicated.
BUPHENYL may be required life-long unless orthotopic liver transplantation is elected.
(See CLINICAL PHARMACOLOGY, Pharmacodynamics subsection for the biochemical effects of BUPHENYL).
Published Studies Related to Buphenyl (Phenylbutyrate)
Randomized, double-blind, controlled study of glycerol phenylbutyrate in hepatic
CONCLUSION: GPB reduced HE events as well as ammonia
Phenylbutyrate Mouthwash Mitigates Oral Mucositis During Radiotherapy or Chemoradiotherapy in Patients with Head and Neck Cancer. [2011.08.11]
CONCLUSIONS: This pilot trial suggested that phenylbutyrate mouthwash significantly decreased the impact of OM in HNC patients receiving RT or chemoradiotherapy and did not confront the tumor control. Larger Phase II randomized trials are needed to confirm these results. Copyright (c) 2011 Elsevier Inc. All rights reserved.
Pharmacology and safety of glycerol phenylbutyrate in healthy adults and adults with cirrhosis. [2010.06]
CONCLUSION: GPB exhibits delayed release characteristics, presumably reflecting gradual PBA release by pancreatic lipases, and is well tolerated in adults with cirrhosis, suggesting that further clinical testing for HE is warranted.
Randomized, double-blind, placebo-controlled trial of phenylbutyrate in spinal muscular atrophy. [2007.01.02]
OBJECTIVE: To assess the efficacy of phenylbutyrate (PB) in patients with spinal muscular atrophy in a randomized, double-blind, placebo-controlled trial involving 10 Italian centers... CONCLUSIONS: Phenylbutyrate was not effective at the regimen, schedule, and duration used in this study.
Evidence of CFTR function in cystic fibrosis after systemic administration of 4-phenylbutyrate. [2002.07]
Most individuals with cystic fibrosis (CF) carry one or two mutations that result in a maturation defect of the full-length protein. One such mutation, deltaF508, results in a mutant membrane glycoprotein that fails to progress to the apical membrane, where the wild-type protein normally functions as a cyclic AMP-regulated chloride channel...
Clinical Trials Related to Buphenyl (Phenylbutyrate)
Pilot Study of Safety and Efficacy of Sodium Phenylbutyrate in Spinocerebellar Ataxia Type 3 [Not yet recruiting]
DESIGN: Pilot, Phase II, double-blind, placebo-controlled study
JUSTIFICATION: In the literature one does not find a pharmacological treatment that changes
the natural history of Spinocerebellar ataxtia type 3 (SCA3). Patients with this disease
invariably become dependent.
OBJECTIVES I. To determine safety and tolerability of phenylbutyrate in patients with SCA3.
II. To provide early subsidies on the efficacy of phenylbutyrate in SCA3.
DURATION: 12 months of a double-blind study.
PLACE OF REALIZATION: Hospital de Clínicas de Porto Alegre, Brazil.
NUMBER OF PATIENTS: 20 patients.
CONCOMITANT MEDICATIONS: There are no concomitant medications that are prohibited unless
they affect safety parameters of this study (hemogram and platelets; fasting serum glucose,
AST, ALT, Gamma-GT, Bilirubins, Prothrombin time, Creatinine, Urea, Na, K, chlorides and
arterial gasometry; electrocardiogram and echocardiogram).
MEDICATIONS UNDER INVESTIGATION: Powdered sodium phenylbutyrate in sachets containing each
3g. At the start of the study, the dose will be 15g/day (five sachets) and may be reduced in
case of mild adverse events.
OUTCOMES Primary safety outcome: The number of adverse events, interruptions and dose
reductions in the two groups (cases and controls).
Efficacy outcomes: Efficacy outcomes are the following scores in both groups: NESSCA, SARA,
Barthel, BDI, and WHOQol.
Clinical Trial of Phenylbutyrate and Vitamin D in Tuberculosis (TB) [Recruiting]
Vitamin D exerts its effects via the Vitamin D Receptor (VDR) present in activated
macrophages and induces expression and release of the cathelicidin, LL-37, a human
antimicrobial peptide involved in killing of MTB. We aimed to investigate whether treatment
of newly diagnosed pulmonary TB patients for 2 months with adjunctive PBA and vitamin D
(Cholecalciferol) in combination with standard DOTS therapy (i) can improve response to
standard short course TB therapy towards a rapid recovery; (ii) can induce expression of
LL-37 in macrophages; (iii) can enhance killing capacity of macrophages isolated from TB
patients infected in vitro with MTB; and (iv) does not evoke any adverse effects.
Phenylbutyrate Therapy for Maple Syrup Urine Disease [Recruiting]
The investigators have learned in past research that the drug phenylbutyrate can decrease
the amounts of branched chain amino acids and their byproducts in the bloodstreams of
healthy volunteer patients and also patients with certain disorders of protein breakdown
including maple syrup urine disease. Through this study, the investigators will try to find
out how well phenylbutyrate (NaPBA), also known by name brand "Buphenyl-TM", decreases BCAA
and branched chain keto chain acids in the blood of patients with MSUD. The investigators
hope is that through this research the investigators will be better able to treat these
Subjects with MSUD will take phenylbutyrate (NaPBA) in powder form for a two-week treatment
period and powder placebo, a substance with no effect on the body, for a two-week treatment
period. They will be given the same amount of powder and undergo the same laboratory
testing during both of the two-week treatment periods. The results will be compared once
the study is over.
Arginine and Buphenyl in Patients With Argininosuccinic Aciduria (ASA), a Urea Cycle Disorder [Recruiting]
Urea cycle disorders are inherited illnesses in which the body does not produce enough of
the chemicals that remove ammonia, a byproduct of protein metabolism, from the blood stream.
Elevated ammonia levels can lead to brain damage and death. Argininosuccinic aciduria (ASA)
is a type of urea cycle disorder that is characterized specifically by high levels of
argininosuccinic acid, a chemical involved in the urea cycle. People with ASA are at risk
for serious liver damage, which may be due to the elevated levels of argininosuccinic acid.
Sodium phenylbutyrate (Buphenyl-TM) is a drug that has been used to treat other types of
urea cycle disorders. This study will evaluate whether Buphenyl-TM in conjunction with
decreased arginine dose (in addition to a normal regimen of protein) will improve short-term
liver function and decrease plasma citrulline and ASA levels in people with ASA.
Safety and Tolerability Study of Phenylbutyrate in Huntington's Disease (PHEND-HD) [Completed]
The purpose of this study is to evaluate the safety, tolerability and clinical impact of
15-grams daily of sodium phenylbutyrate (phenylbutyrate) in Huntington's disease and to lay
the groundwork for possible subsequent trials designed to specifically address its ability to
slow or halt the progression of the disease.
Page last updated: 2014-11-30